RE:RE:RE:EY sees bolt-ons in the single to double digit billions now
And the barking dogs probably also saw what Subin Baral, a partner at Ernst & Young LLP and EY Global Life Sciences Deals Leader, recently said about projected short-term trends for biopharma M&A with GEN Edge.
Subin Baral: We’ve seen some of the recent deals that Pfizer’s done, most recently its deal with Biohaven, and the deal GSK did to acquire Sierra Oncology. You are seeing a lot of deals coming back, with the biotechs having the opportunity to partner with the big biopharma companies, or be acquired by them.
You never say never to megadeals, such as the $20-30-plus billion deals. But a lot of these bolt-ons, in the single- to double-digit billions, are in play in our view, if you look at macroeconomic trends and the headwinds with geopolitical issues.